Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs NeuroSense Therapeutics Ltd. (NRSN)

Alzamend Neuro, Inc. and NeuroSense Therapeutics Ltd. are both Biotechnology companies. Alzamend Neuro, Inc. and NeuroSense Therapeutics Ltd. are of similar size ($6.2M and $6.0M). Across the 7 metrics below, Alzamend Neuro, Inc. leads on 4 and NeuroSense Therapeutics Ltd. on 3.

Valuation

Metric ALZN NRSN Biotechnology median
P/E n/m n/m 8.50
P/S n/m n/m 9.71
P/B 1.02 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.15 n/m 0.64
EV/Sales n/m n/m 9.21
Earnings yield (174.24%) (406.90%) (33.15%)
Free cash flow yield (120.83%) (444.35%) (25.50%)

Profitability

Metric ALZN NRSN Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) 0.00% (56.36%)
Return on assets (122.36%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN NRSN Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 76.77% 18.52% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN NRSN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 0.28 4.72
Net debt to EBITDA 0.08 0.01 0.96

Dividend

Metric ALZN NRSN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ALZN NRSN Biotechnology median
Market cap 6.17m 6.01m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack